6/28/23, 11:22 PM NONS Pathway Feedback Search Clinical Topics Home Studies NONS NONS Disease COVID 19 infection Trial question What is the role of novel nitric oxide nasal spray in patients with recent COVID-19 infection? Study design Multi-center Double blinded RCT Population Characteristics of study participants 36.0% female N = 306 64.0% male 306 patients (109 female, 197 male) Inclusion criteria: adult patients with mild symptomatic COVID-19 Key exclusion criteria: requirement of oxygen support and hospitalization; pneumonia; pregnancy; allergy to nitric oxide nasal spray; asthma Interventions N=153 nitric oxide nasal spray (self-administered 6 times a day as 2 sprays per nostril for 7 days) N=153 placebo (matching placebo nasal spray for 7 days) Primary outcome Reduction in viral ribonucleic acid load at day 8 2.6 log10 2.62 https://web.pathway.md/studies/recrX82ZpjhPHV9JP 1/2 6/28/23, 11:22 PM NONS Pathway g 6 2.1 2.0 log10 1.3 log10 0.7 log10 Significant increase 0.0 log10 Nitric oxide nasal spray Placebo Significant increase in reduction in viral RNA load at day 8 (2.62 log10 copies/mL vs. 2.1 log10 copies/mL; AD 0.52 log10 copies/mL, 95% CI 0.12 to 0.92) Secondary outcomes Significant increase in the percentage of patients with negative conversion of RT-PCR at day 8 (82.8% vs. 66.7%; AD 16.1%, 95% CI 0.2 to 32.1) Significant decrease in time to negative conversion of RT-PCR (3 days vs. 7 days; AD -4 days, 95% CI -7.9 to -0.1) No significant difference in the percentage of patients with 2% improvement in the WHO Clinical Progression Scale score at day 8 (78.1% vs. 62.3%; AD 15.8%, 95% CI -1 to 32.6) Safety outcomes No significant differences in metHgb levels, nasal vasodilation symptoms, systemic vasodilation signs. Conclusion In adult patients with mild symptomatic COVID-19, nitric oxide nasal spray was superior to placebo with respect to reduction in viral RNA load at day 8. Reference Monika Tandon, Wen Wu, Keith Moore et al. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomised trial. Lancet Reg Health Southeast Asia. 2022 Jun 29;3:100036. Open reference URL https://web.pathway.md/studies/recrX82ZpjhPHV9JP 2/2